Literature DB >> 6388814

The role of surgery in advanced testicular cancer.

J P Donohue, R G Rowland.   

Abstract

Advanced testicular cancer is best treated with combination platinum-based chemotherapy as primary therapy. If there is only moderate tumor bulk at presentation, many patients will achieve a complete remission and have no evidence of disease thereafter. Those with more bulky tumor who obtain a partial remission should then have residual tumor completely resected by surgery. This effectively restages the patient, provides therapeutic benefit to many, and determines the need for additional chemotherapy. If carcinoma is found in the resected specimen, further "salvage" chemotherapy is required. If the resection is grossly complete, even this group can obtain survival in the majority of cases.

Entities:  

Mesh:

Year:  1984        PMID: 6388814     DOI: 10.1002/1097-0142(19841201)54:2+<2716::aid-cncr2820541418>3.0.co;2-h

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

Review 1.  Late relapse of testicular cancer.

Authors:  Martin E Lipphardt; Peter Albers
Journal:  World J Urol       Date:  2004-04-03       Impact factor: 4.226

2.  Metastatic testicular germ cell tumour: the role of salvage surgery.

Authors:  K Suzuki; K Kurokawa; T Suzuki; S Jinbo; M Kobayashi; K Imai; H Yamanaka
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

3.  Mediastinal germ cell tumour with massive pulmonary involvement.

Authors:  Kenji Kawamukai; Salomone Di Saverio; Filippo Antonacci; Nicola Lacava; Maurizio Boaron
Journal:  BMJ Case Rep       Date:  2011-08-11

Review 4.  Biology of metastases and its clinical implications: testicular germ-cell tumors.

Authors:  J P Donohue; R S Foster; J S Little; P J Loehrer; L E Einhorn
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

5.  Size and status of metastases after inductive chemotherapy of germ-cell tumors. Indication for salvage operation.

Authors:  N Jaeger; L Weissbach; R Bussar-Maatz
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

Review 6.  Persistent cancer in postchemotherapy retroperitoneal lymph-node dissection: outcome analysis.

Authors:  J P Donohue; E P Fox; S D Williams; P J Loehrer; T M Ulbright; L H Einhorn; T D Weathers
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

7.  Late relapse after treatment for nonseminomatous testicular germ cell tumors according to a single center-based experience.

Authors:  M A Kuczyk; C Bokemeyer; C Kollmannsberger; S Corvin; A Anastasiadis; S Machtens; A Merseburger; G Wegener; A Stenze; J T Hartmann; U Jonas
Journal:  World J Urol       Date:  2004-04       Impact factor: 4.226

8.  Prognosis after resection of residual masses following chemotherapy for metastatic nonseminomatous testicular cancer: a multivariate analysis.

Authors:  E W Steyerberg; H J Keizer; J Zwartendijk; G L Van Rijk; C J Van Groeningen; J D Habbema; G Stoter
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

9.  Long-term follow-up of residual masses after chemotherapy in patients with non-seminomatous germ cell tumours.

Authors:  M P Napier; A Naraghi; T J Christmas; G J Rustin
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

10.  Sequential resection of residual abdominal and thoracic masses after chemotherapy for metastatic non-seminomatous germ cell tumours.

Authors:  A Gerl; C Clemm; N Schmeller; H Dienemann; M Weiss; M Kriegmair; U Löhrs; W Wilmanns
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.